Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25775848 | 0.88 | HDAC6 (0.48) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23977585 | 0.87 | HRH3 (0.33) | CNR2HDAC6KMT2AF12ALDH1A1 | |
| SCHEMBL15009312 | 0.79 | CA12 (0.54) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15009659 | 0.75 | LOXL2 (0.45) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23977808 | 0.74 | CNR2 (0.42) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25775849 | 0.74 | HDAC6 (0.45) | HDAC6 | |
| SCHEMBL3362801 | 0.69 | HDAC6 (0.63) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15013179 | 0.69 | CYP2A6 (0.50) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15008756 | 0.69 | MEN1 (0.54) | CNR2HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15009596 | 0.68 | CNR2 (0.60) | CNR2HDAC6SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | TNF, GCDH, LITAF | CNR2 2547/4885HDAC6 452/4885SMN1; SMN2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.